Nektar Therapeutics (India) Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
as on 10-07-2024
- Paid Up Capital ₹ 29.39 Cr
as on 10-07-2024
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 22.60%
(FY 2022)
- Profit -364.93%
(FY 2022)
- Ebitda 10.67%
(FY 2022)
- Net Worth -16.12%
(FY 2022)
- Total Assets 3.67%
(FY 2022)
About Nektar Therapeutics (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 29.39 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Nektar Therapeutics (India) Private Limited India is Phaneendra Modali as COMPANY SECRETARY. Uday Yemmanuru and Mark Wilson serve as directors at the Company.
- CIN/LLPIN
U24239TG2005FTC046253
- Company No.
046253
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
16 May 2005
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Nektar Therapeutics (India) Private Limited offer?
Nektar Therapeutics (India) Private Limited offers a wide range of products and services, including .
Who are the key members and board of directors at Nektar Therapeutics (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Phaneendra Modali | Company Secretary | 16-Jul-2018 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uday Yemmanuru  | Additional Director | 30-Mar-2024 | Current |
Mark Wilson  | Director | 19-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Nektar Therapeutics (India).
Nektar Therapeutics (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.6% increase. The company also saw a substantial fall in profitability, with a 364.93% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nektar Therapeutics (India)?
In 2021, Nektar Therapeutics (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nektar Therapeutics (India)?
Nektar Therapeutics (India) has a workforce of 3 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nektar Therapeutics (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nektar Therapeutics (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
